Lymphoma Clinical Trials

85 studies are recruiting for lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. Mosunetuzumab for CLL MRD Clearance

   The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigham & Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Inhye Ahn

   See if you can join NCT07052695 on ClinicalTrials.gov

2. Living Well With Lymphoma

   In this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persiste…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT06047626 on ClinicalTrials.gov

3. Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

   RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic c…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT01137643 on ClinicalTrials.gov

4. WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

   The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG)…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07058064 on ClinicalTrials.gov

5. Umbilical Cord Blood Transplantation From Unrelated Donors

   This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-fr…

   Stage

   Not phased

   Ages

   0 to 75

   Site

   Wilmot Cancer Institute, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT03016806 on ClinicalTrials.gov

6. Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

   The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York

   Locations

   2 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05940272 on ClinicalTrials.gov

7. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov

8. HEME Home Transfusion Program

   This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancie…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06487247 on ClinicalTrials.gov

9. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

   This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will incl…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Davis, Sacramento, California

   Locations

   2 in total

   Run by

   Estrella Biopharma, Inc.

   See if you can join NCT06343311 on ClinicalTrials.gov

10. A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

    This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and max…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Run by

    Fox Chase Cancer Center

    See if you can join NCT04827810 on ClinicalTrials.gov